Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficlatuzumab + Cetuximab in R/M HPV-Negative HNSCC
NCT06064877Phase 3Recruiting
- Sponsor
- AVEO Oncology
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of ficlatuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by AVEO Oncology. Started Jan 2024; status: recruiting.
02
Drugs
ficlatuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06064877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064877.